The story of Sildenafil presents a complex case for investors in the drug sector. While initially a blockbuster success, generating billions, the intellectual property end and the subsequent entry of off-brand versions https://pharma463913.bloggin-ads.com/64921332/the-little-copyright-and-big-pharma-a-hazardous-investment